Abbott Laboratories vs. Tempest Therapeutics, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| ABT | TPST | |
|---|---|---|
| Market Cap | $194.62 billion | $17.53 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-40,472,000 |
ABT leads on 2 of 2 size & scale factors.
Valuation
| ABT | TPST | |
|---|---|---|
| P/E Ratio | 36.40 | — |
| Price / Book | 3.76 | -16.08 |
| Price / Sales | 4.18 | — |
TPST leads on 1 of 1 valuation factors.
Profitability
| ABT | TPST | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | 3713.03% |
TPST leads on 1 of 1 profitability factors.
Dividend
| ABT | TPST | |
|---|---|---|
| Dividend Yield | 2.24% | — |
| Payout Ratio | 81.55 | — |
ABT and TPST split the dividend factors evenly.
Risk & Sentiment
| ABT | TPST | |
|---|---|---|
| Short Interest | 0.57% | 1.07% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, TPST overview, TPST financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.